MeiraGTx Holdings plc
MGTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, MeiraGTx Holdings plc focuses on Biotechnology services and products. MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. At a $884.6M market cap, MeiraGTx Holdings plc ranks as a small-cap company within healthcare. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Market Cap
$884.6M
Beta
1.35
P/E (TTM)
10.59
P/E (Fwd)
-6.04
EPS (TTM)
$0.87
EPS (Fwd)
$-1.52
ROE
72.2%
ROA
38.6%
Cash
$143.2M
Total Debt
$112.3M
Free CF
$56.4M
52W Change
3.8%
Annual Financials
Cash vs Debt
Where MGTX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, MGTX finished 16.25% below its 150-day moving average ($11.08) and 9.11% below its 200-day moving average ($10.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MGTX overbought or oversold?
At the October 19, 2026 close, MGTX's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $143.2M in cash and $112.3M in debt, MGTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $56.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 72.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 38.6% further supports the picture of efficient asset utilization. Revenue has grown from $15.9M (2022) to $81.4M (2025), reflecting a 411% increase over the period.
Investors considering MeiraGTx Holdings plc should weigh the typical risks associated with MGTX's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MeiraGTx Holdings plc's trajectory.